FOR-6219 shows promise in Phase I endometriosis trial
FOR-6219 was found to be safe and well tolerated by…
FOR-6219 was found to be safe and well tolerated by healthy pre- and postmenopausal women and did not induce systemic oestrogen deficiency-related side effects.